Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended			124 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012
Licensing revenue	$ 2,446,105	$ 1,805,130	$ 0	$ 4,251,235
Costs and expenses:
Research and development	16,182,564	11,426,155	12,709,590	71,434,691
General and administrative	5,177,129	4,209,429	3,643,623	29,598,082
Total costs and expenses	21,359,693	15,635,584	16,353,213	101,032,773
Other income (expense):
Revaluation of warrants	(24,625,598)	1,044,826	672,477	(23,075,576)
Foreign currency loss on liquidation	(191,733)	0	0	(191,733)
Other income, net	87,848	47,974	104,554	1,376,538
QTDP Grant	0	0	488,959	488,959
Total Other income (expense)	(24,729,483)	1,092,800	1,265,990	(21,401,812)
Net loss	(43,643,071)	(12,737,654)	(15,087,223)	(118,183,350)
Dividends on preferred stock, not declared	(2,630,435)	(3,000,000)	(2,901,370)	(10,944,134)
Net loss attributable to common stockholders	(46,273,506)	(15,737,654)	(17,988,593)	(129,127,484)
Net loss per share, basic and diluted (in dollars per share)	$ (7.36)	$ (4.73)	$ (5.40)
Weighted average shares outstanding, basic and diluted (in shares)	6,283,238	3,329,666	3,329,666
Other comprehensive gain/(loss):
Unrealized (loss) on investment securities	(21,451)			(21,451)
Foreign currency translation adjustments	184,500	(6,345)	(100,035)	0
Total comprehensive loss	$ (43,480,022)	$ (12,743,999)	$ (15,187,258)	$ (118,204,801)